PUBLICATIONS

In clinical research, translation is essential. Every patient deserves to fully understand their consent. Unfortunately, many critical documents like informed consent forms and trial instructions are inadequately translated, leading to confusion, misinformed choices, and potential safety risks.

In an era of digital transformation, companies seeking sustainable growth are turning to innovative solutions that streamline processes, increase productivity and deliver the highest quality of service. At Janus Worldwide, the answer to these challenges is the Maia project, an internal AI ecosystem that integrates artificial intelligence and key enterprise tools into a single entity.

Janus successfully uses various automated translation technologies: machine translation (MT) and translation using artificial intelligence. As well as advantages, both technologies have their disadvantages, which are offset by certain customization methods, making each technology suitable for specific translation tasks.

Medical translations are not just words on paper — they are a lifeline for patients, healthcare professionals, and medical device users worldwide. A single mistranslation can lead to misdiagnosis, ineffective treatment, or even death. Understanding the risks and knowing how to avoid them is critical for any healthcare provider, medical device manufacturer, or pharmaceutical company.

In the highly regulated environment of EU clinical trials, safeguarding personal data and commercially confidential information (CCI) is critical – not only for legal compliance, but also for maintaining trust among stakeholders. For companies leveraging translation and localization services to support global clinical research, understanding how these services intersect with data protection regulations such as the GDPR and EMA policies is essential. Janus Worldwide plays a pivotal role in ensuring the confidentiality and security of sensitive information through industry-leading localization solutions.